title: Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells.
abstract: Suberoyl bis‑hydroxamic acid (SBHA) is a histone deacetylase inhibitor that has shown anticancer activity against numerous types of human cancer. The aim of the current study was to explore the effects of SBHA on the proliferation and apoptosis of breast cancer cells. MCF‑7 breast cancer cells were treated with different concentrations of SBHA and tested for cell viability, apoptosis and gene expression changes. The results showed that SBHA significantly inhibited the proliferation of MCF‑7 cells in a concentration‑dependent manner, as determined using a Cell Counting kit‑8 assay. SBHA‑treated MCF‑7 cells showed G0/G1 cell‑cycle arrest, coupled with elevated expression levels of p21 and p27 proteins. Hoechst 33258 staining revealed cell shrinkage, chromosomal condensation and nuclear fragmentation in MCF‑7 cells treated with SBHA. Flow cytometric analysis of Annexin V‑stained cells showed that SBHA treatment induced apoptotic cell death in a concentration‑dependent manner. Western blot analysis confirmed the upregulation of Bax and the downregulation of Bcl‑2 by SBHA. In conclusion, these results indicate that SBHA exerts cytotoxic effects against human breast cancer cells, which involves the modulation of p21, p27 and Bcl‑2 family proteins, consequently leading to cell‑cycle arrest and apoptosis.
authors.affiliation: Department of Medical Oncology, Minhang Branch of Fudan University Shanghai Cancer Center, Shanghai 200240, P.R. China.
authors.forename: Xinmiao
authors.initials: X
authors.lastname: Yang
authors.affiliation: Department of Medical Oncology, Minhang Branch of Fudan University Shanghai Cancer Center, Shanghai 200240, P.R. China.
authors.forename: Ning
authors.initials: N
authors.lastname: Zhang
authors.affiliation: Department of Radiation Oncology, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 200233, P.R. China.
authors.forename: Zeliang
authors.initials: Z
authors.lastname: Shi
authors.affiliation: Department of Radiation Oncology, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 200233, P.R. China.
authors.forename: Zhangyu
authors.initials: Z
authors.lastname: Yang
authors.affiliation: Department of Medical Oncology, Fudan University Cancer Hospital, Shanghai 200032, P.R. China.
authors.forename: Xichun
authors.initials: X
authors.lastname: Hu
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D015870:Gene Expression; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology*; D061986:MCF-7 Cells; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D051028:bcl-2-Associated X Protein / Q000235:genetics / Q000378:metabolism
chemical_list: D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D019253:Proto-Oncogene Proteins c-bcl-2; D051028:bcl-2-Associated X Protein; C528828:suberoyl bis-hydroxamic acid